कंपनी लोड हो रही है
Just reported
Q3 2026 results
From Viatris's results release of 5 नवंबर 2026; its quarterly report has since been filed.
Revenue
Actual
$3.75B
-0.3% y/y
-0.2% q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0.28
Guided
—
No guide given
EPS, adjusted: $0.71
Operating income, GAAP
Actual
$261.5M
+46% y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Viatris is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$34.4BA
NBIXNeurocrine Biosciences, Inc.$16.9BA+
ELANElanco Animal Health Incorporated$13.4BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now A
Viatris Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
